Skip to main content
. 2012 Feb 27;14(2):204–221. doi: 10.1038/aja.2011.104

Table 3. Summary of baseline values in studies examining measures of body composition in men with prostate cancer treated with androgen deprivation therapy of different durations compared with control groups with and without prostate cancer.

Type of study Time on ADT (month) at baseline N Age (y) Baseline values References
Table 3A Body mass index (kg m−2)
P-Long 3.8 12 74 28.7 Levy et al.,35 2008
  24.6 23 71 29.6  
  PCa-0 or HC 13 67 28.7  
P-Long 3.0 43 71 28.4 van Londen et al.,105 2008
  30.7 67 71 29.1  
  PCa-0 81 67 28.3  
  HC 53 63 27.6  
P-Long 0 32 66 26.9 Smith et al.,104 2002
P-Long 0 79 71 28.4 Smith et al.,129 2004
P-Long 0 35 75 25.9 Berruti et al.,106 2002
  11.6 50 73 25.3 Denti et al.,130 1996
  HC 58 74 24.4  
P-Long 0 10 74 25.2 Tayek et al.,131 1990
P-Long PCa-0 18 67 24.7 Nowicki et al.,132 2001
P-Long 0 25 68 29.1 Smith et al.,107 2006
P-Long 0-12 26 65 27.1 Smith et al.,100 2008
P-Long 0 62 69 25.4 Stone et al.,25 2000
RCT 18.2 29 70 27.4 Galvao et al.,92 2010
  10.1 28 70 28.0  
RCT 3 (median) 120 72 28.8 Ryan et al.,134 2007
CS 3.7 13 73 28.3 Clay et al.,34 2007
  30.7 42 74 28.1  
  PCa-0 25 65 28.0  
  HC 20 69 27.6  
CS >12 20 74 26.6 Soyupek et al.,23 2008
  HC 20 73 25.9  
CS 45 20 70 29.6a Basaria et al.,26 2002
  PCa-0 18 66 27.6  
  HC 20 69 24.7b  
CS <6 24 74 28.6 Dacal et al.,109 2006
  ≥6 29 73 27.4  
  PCa-0 23 64 28.5  
  HC 20 64 26.9  
CS 12-60 62 74 27.4a Chen et al.,101 2002
  HC 47 73 25.8a  
CS >6 30 72 26.8 Boxer et al.,96 2005
  HC 25 75 26.1  
CS PCa-0 11 69 28.4 Maturo et al.,110 2003
  HC 11 70 27.6  
CS >6 63 68 28.7 Culos-Reed et al.,36 2010
CS 41 19 72a 28.0 Stoch et al.,1 2001
  PCa-0 41 70b 26.6  
  HC 197 66a,b 27.9  
CS PCa-0 155 68 28.8 Segal et al.,117 2003
CS 37 10 70 28.0 Galvao et al.,37 2006
Table 3B Percent Lean body mass
P-Long 3.8 12 74 70.9 Levy et al.,35 2008
  24.6 23 71 65.6  
  PCa-0 or HC 13 67 72.3  
P-Long   65a 66 69.7 Lee et al.,99 2005
P-Long 3.0 43 71 69.9 van Londen et al.,105 2008
  30.7 67 71 65.9  
  PCa-0 81 67 70.3  
  HC 53 63 71.6  
P-Long 0 32 66 70.3 Smith et al.,104 2002
P-Long PCa 79 71 68.7 Smith et al.,103 2004
P-Long 0 72 74 55.8 kg Galvao et al.,95 2008
P-Long 0 35 75 68.5 Berruti et al.,106 2002
P-Long 0 25 68 68.1 Smith et al.,107 2006
RCT 18.2 29 70 69.5 Galvao et al.,92 2010
  10.1 28 70 69.5  
CS 3.7 13 73 71.1c Clay et al.,34 2007
  30.7 42 74 66.7a–c  
  PCa-0 25 65 71.1a  
  HC 20 69 71.2a  
CS <6 24 74 68.1 Dacal et al.,109 2006
  ≥6 29 73 66.8  
    P<0.01 for ADT groups vs. no ADT groups
  PCa-0 23 64 70.7  
  HC 20 64 72.2  
CS 12-60 62 74 64.2 Chen et al.,101 2005
  HC 47 73 70.6  
CS >6 30 72 53.3 Boxer et al.,96 2005
  HC 25 75 54.3  
CS PCa-0 11 69 65.1a Maturo et al.,110 2003
  HC 11 70 67.3a  
CS 41 19 72a 71.0 Stoch et al.,1 2001
  PCa-0 41 70a 75.0  
  HC 197 66a,b NA  
Appendicular skeletal muscle mass (kg)
P-Long 0 72 74 23.4 Galvao et al.,95 2008
Appendicular skeletal muscle mass index (ASM Ht−2)
CS >6 30 72 7.5 Boxer et al.,96 2005
  HC 25 75 7.5  
Table 3C Percent relative body fat</emph>
P-Long 3.8 12 74 26.5 Levy et al.,35 2008
  24.6 23 71 31.6  
  PCa-0 or HC 13 67 24.7  
P-Long 35 65d 66 27.1 Lee et al.,99 2005
P-Long 0 26 65 25.1 Smith et al.,112 2004
P-Long 0 25 68 28.7 Smith et al.,107 2006
P-Long 0 79 71 28.0 Smith et al.,103 2004
P-Long 3.0 43 71 27.1 van Londen et al.,105 2008
  30.7 67 71 31.4  
  0 81 67 26.7  
  HC 53 63 25.1  
P-Long 0 32 66 26.4 Smith et al.,104 2002
P-Long 0 72 74 25.8 Galvao et al.,95 2008
P-Long 0 35 75 24.7 Berruti et al.,106 2002
P-Long >6 30 72 29.8a Boxer et al.,96 2005
  HC 25 75 26.6a  
RCT 18.2 29 70 27.5 Galvao et al.,92 2010
  10.1 28 70 27.3  
CS 3.7 13 73 26.2c Clay et al.,34 2007
  30.7 42 74 30.5a–c  
  PCa-0 25 65 25.9a  
  HC 20 69 25.6b  
CS 45 20 70 32.2a,b Basaria et al.,26 2002
  PCa-0 18 66 26.2a  
  HC 20 69 22.4b  
CS <6 24 74 29.0 Dacal et al.,109 2006
  ≥6 29 73 30.2  
    P<0.01 for ADT groups vs. no ADT groups  
  PCa-0 23 64 26.3  
  HC 20 64 24.6  
CS 12-60 62 74 30.2a Chen et al.,101 2002
  HC 47 73 25.7a  
CS PCa-0 11 69 29.5 Maturo et al.,110 2003
  HC 11 70 29.6  
CS 41 19 72a 29 Stoch et al.,1 2001
  PCa-0 41 70b 25  
  HC 197 66a,b NA  
CS 37 10 70 30.7 Galvao et al.,37 2006

Abbreviations: ASM, appendicular skeletal muscle mass; ASM Ht−2, appendicular skeletal muscle mass index, ASM divided by height squared; CS, cross-sectional; HC, healthy control; PCa-0, patients with PCa but not using ADT; P-Long, prospective-longitudinal; RCT, randomized controlled trial.

a–c

Identical symbols represent significant differences between groups within a study.

d

35% of the 65 subjects had received GnRH agonist treatment for 35 months before entry into study. The remainder began ADT and continued treatment over the 12-month study duration.